CSIMarket Company Name, Ticker, Industry, else..
 
Springworks Therapeutics Inc   (NASDAQ: SWTX)
Other Ticker:  
 
 
Price: $36.1600 $0.02 0.055%
Day's High: $37.29 Week Perf: 4.42 %
Day's Low: $ 35.67 30 Day Perf: 1.6 %
Volume (M): 1,356 52 Wk High: $ 53.92
Volume (M$): $ 49,015 52 Wk Avg: $39.79
Open: $35.72 52 Wk Low: $28.21



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 62
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -325
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 15

Springworks Therapeutics Inc
Springworks Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with severe rare diseases and cancer. The company's primary goal is to address unmet medical needs and improve patients' lives by advancing its robust pipeline of therapeutic candidates. Springworks Therapeutics utilizes a strategic approach that leverages its deep expertise in clinical development and collaboration with partners to efficiently bring promising therapies to market. They aim to make a significant impact on patient outcomes by discovering and developing transformative therapies.


   Company Address: 100 Washington Blvd Stamford 6902 CT
   Company Phone Number: 883-9490   Stock Exchange / Ticker: NASDAQ SWTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN      % 
APTO      % 
EXEL      % 
GILD      % 
INTS      % 
IOVA      % 
• View Complete Report
   



Clinical Study

Mirdametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas Pivotal Phase 2b ReNeu Trial Outcomes a...

Published Mon, Nov 11 2024 11:31 AM UTC

Abstract Neurofibromatosis type 1 (NF1) is a neurogenetic disorder characterized by the development of multiple tumors, most notably plexiform neurofibromas (NF1-PN). These tumors often lead to significant morbidity, impacting patient quality of life. This article presents an extensive review of the pivotal Phase 2b ReNeu trial results evaluating the efficacy and safety of m...
Clinical Study

SpringWorks Therapeutics Unveils Promising Long-Term Findings for OGSIVEO in Desmoid Tumors at 2024 CTOS Annual Meeting

Published Thu, Nov 7 2024 11:30 AM UTC

As the field of oncology continues to advance, the importance of long-term efficacy and safety data remains paramount in the development of novel therapeutics. SpringWorks Therapeutics Inc. (NASDAQ: SWTX) has made significant strides in this arena, announcing compelling findings from its Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in adults diagnosed with desmoid tumors, wh...
Clinical Study

Priority Review and Rolling Submission of Mirdametinib for NF1-PN Advancing Treatment for a Rare Genetic D...

Published Wed, Aug 28 2024 10:31 AM UTC

Abstract Recent advancements in the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) have centered around SpringWorks Therapeutics investigational MEK inhibitor, mirdametinib. This article provides an in-depth examination of the U.S. Food and Drug Administration (FDA) granting priority review to the New Drug Application (NDA) for mirdametini...
Product Service News

SpringWorks Therapeutics Takes Stride Towards Augmenting NF1 Treatment with Mirdametinib NDA Submission ...

Published Mon, Jul 1 2024 10:30 AM UTC

SpringWorks Therapeutics Submits New Drug Application to FDA for Mirdametinib in Treatment of Neurofibromatosis Type 1-Plexiform NeurofibromasSTAMFORD, Conn., July 01, 2024 - SpringWorks Therapeutics, a leading biopharmaceutical company specializing in severe rare diseases and cancer, announced today the successful completion of the New Drug Application (NDA) submission to t...
Springworks Therapeutics Inc

SpringWorks Therapeutics Inc. Holds Strong Financial Grounds in Q1 2024, Break-Even Earnings Achieved

SpringWorks Therapeutics Inc, a biopharmaceutical company known for its innovative treatment modalities, has reported its financial results for the first quarter of 2024. The company achieved break-even earnings per share of $0.00, which is consistent with the previous year's performance and an improvement from the previous reporting season. Revenue remained steady at $0.00 million, indicating a strong performance compared to the same period a year ago and sequentially from the previous quarter.
Despite these positive financial indicators, SpringWorks Therapeutics Inc reported an unchanged net loss of $0.000 million in the first quarter of 2024. However, the company's accomplishments extend beyond financial metrics, as they announced that their abstracts have been accepted for presentation at the prestigious 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com